European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma
(WorldNews France)

European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma 02 Jun 2020 12:47 CEST Company Name SANOFI ISN FR0000120578 Market Euronext Symbol SAN European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex) Sarclisa in combination with pom-dex significantly reduced the risk of progression or death by...